As covered on PharmaBiz, Roche has reported topline results from the phase III persevERA Breast Cancer study, which evaluated the oral selective oestrogen receptor degrader (SERD) giredestrant in combination with the CDK4/6 inhibitor palbociclib as first-line therapy for patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer. While the study showed a numerical improvement in outcomes, it did not achieve its primary endpoint of statistically significant progression-free survival (PFS) benefit compared with standard therapy.
The randomized, double-blind, global trial enrolled 992 patients and compared giredestrant plus palbociclib with letrozole plus palbociclib. Investigator-assessed PFS in the intent-to-treat population served as the primary endpoint. According to Roche, the experimental regimen did not demonstrate a statistically significant advantage, although safety findings were consistent with the established profiles of the individual agents and considered manageable.
Despite the negative primary outcome, Roche emphasized its continued confidence in giredestrant as a next-generation endocrine therapy. Levi Garraway, MD, PhD, Roche’s chief medical officer and head of global product development, noted that the company still sees potential for giredestrant in combination with CDK4/6 inhibitors, particularly in earlier disease settings. Ongoing and planned studies are expected to further clarify where the therapy may deliver the greatest benefit.
Broader Clinical Development Strategy
The persevERA trial represents one component of a broad, stage-specific clinical development programme for giredestrant. Importantly, it is the first of two phase III studies evaluating the agent in the first-line advanced breast cancer setting. A second trial, pionERA, is examining giredestrant combined with a physician’s choice of CDK4/6 inhibitor in patients with endocrine-resistant ER-positive, HER2-negative disease, with results anticipated in 2027.
Giredestrant has already generated positive phase III data in other settings. The evERA study, which assessed giredestrant plus everolimus in advanced disease, delivered the first successful late-stage readout for the drug. In early-stage breast cancer, the lidERA trial is evaluating giredestrant as adjuvant endocrine therapy. The scientific rationale for lidERA builds on neoadjuvant evidence, including the phase II coopERA study, which demonstrated greater suppression of tumour cell proliferation (measured by Ki67) with giredestrant compared with aromatase inhibitor therapy.
These findings collectively support the biological activity of giredestrant and reinforce Roche’s strategy of tailoring development to the distinct mechanisms driving disease at different stages.
Regulatory Progress and Next Steps
On the regulatory front, the US Food and Drug Administration has accepted a New Drug Application for giredestrant based on data from the evERA trial. Roche has also indicated that it plans to submit phase III lidERA results in early-stage breast cancer to the FDA in the near term. Full data from persevERA are expected to be presented at a forthcoming scientific congress, which may provide additional insights into subgroup effects and secondary endpoints such as overall survival and response rates.
About Giredestrant
Giredestrant is an investigational, orally administered SERD designed to fully antagonize and degrade the oestrogen receptor. By preventing oestrogen binding and promoting receptor breakdown, the therapy aims to inhibit hormone-driven tumour growth. Roche is currently investigating giredestrant across five company-sponsored phase III trials spanning adjuvant, first-line, and later-line treatment settings, as well as in combination with targeted agents including CDK4/6 inhibitors, everolimus, and HER2-directed therapy.
Unmet Need in ER-Positive Breast Cancer
ER-positive disease accounts for roughly 70% of all breast cancer diagnoses and remains biologically complex and challenging to manage. In early-stage disease, up to one-third of patients experience recurrence despite adjuvant endocrine therapy, often compounded by treatment-limiting tolerability issues. In advanced disease, resistance to endocrine therapies—particularly following CDK4/6 inhibitor exposure—continues to drive progression and poor outcomes.
Against this backdrop, the need for more effective and durable endocrine-based strategies remains urgent. While persevERA did not meet its primary endpoint, Roche maintains that the totality of evidence supports continued development of giredestrant, with the goal of improving long-term outcomes and reducing treatment burden for patients with ER-positive breast cancer.
